drugset / Trial / NCT03722589

Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

NCT03722589

RandomizedParallel-groupOpen-labelPrevention

Summary

This randomized, open-label trial will assess humoral and cell-mediated immune responses to cell culture-based and recombinant unadjuvanted quadrivalent influenza vaccines compared to conventional egg-based unadjuvanted quadrivalent standard dose (15µg of HA per strain) influenza vaccines among persons aged 18-64 years. The trial will be conducted at two sites in the United States during two influenza seasons (2018-19 and 2019-20). Stratified enrollment procedures will be used to enroll a mix of participants based on age.

Timeline

Start
2018-09-12
Primary completion
2020-07-31
Completion
2020-07-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Flublok Vaccine 0.5 ml Intramuscular
Comparator Flucelvax Vaccine 0.5 ml Intramuscular
Comparator Influenza Virus Vaccine Vaccine 0.5 ml Intramuscular

Indications